Trials / Available
AvailableNCT02209441
Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
* To determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of sorafenib in combination with FOLFOX4 (oxaliplatin/leucovorin/5-fluorouracil) as first-line treatment for advanced gastric cancer * The design of the study incorporated a standard 3 + 3 dose escalation procedure to guide elevation of the sorafenib dosage to the next level
Detailed description
-Twice-daily dosing of sorafenib 200 mg in combination with FOLFOX4 proved effective and safe for the treatment of advanced gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Phase I Dose-finding Study of Sorafenib Study |
Timeline
- First posted
- 2014-08-06
- Last updated
- 2014-08-06
Source: ClinicalTrials.gov record NCT02209441. Inclusion in this directory is not an endorsement.